Clinical pharmacology-how it shapes the drug development journey

被引：0
作者：
Kruse, Matthias [1 ]
Stankeviciute, Simona [2 ]
Perry, Sheryl [3 ]
机构：
[1] Parexel Int GmbH, Berlin, Germany
[2] Parexel Int UAB, Vilnius, Lithuania
[3] PAREXEL Int Ltd, Uxbridge, England
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2025年 / 81卷 / 04期
关键词：
Clinical pharmacology; Drug development; Pharmacokinetics; Pharmacodynamics; Model informed drug development; Artificial intelligence;
D O I：
10.1007/s00228-025-03811-z
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Every drug development is a complex and long journey. Clinical pharmacology is an essential discipline in modern drug development. With its applications, computational modelling, and simulation techniques, it can significantly contribute to the efficiency in drug development today. In this perspective, we highlight why pharmacokinetics and pharmacodynamics are important, what developers need to consider in their clinical development programme, how modelling influences the development process, and discuss recent trends such as artificial intelligence and machine learning that have the potential to reshape future drug development.
引用
收藏
页码：597 / 604
页数：8
相关论文
共 30 条
  • [1] Clinical Pharmacology in Drug Development for Rare Diseases in Neurology: Contributions and Opportunities
    Abuasal, Bilal
    Ahmed, Mariam A.
    Patel, Priyank
    Albusaysi, Salwa
    Sabarinath, Sreedharan
    Uppoor, Ramana
    Mehta, Mehul
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (04) : 786 - 798
  • [2] Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases
    Ahmed, Mariam A.
    Burnham, Janelle
    Dwivedi, Gaurav
    AbuAsal, Bilal
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2023, 50 (06) : 429 - 444
  • [3] [Anonymous], 2023, FDA C USE BIOMARKERS
  • [4] Chan D., 2017, International Journal of Pharmacokinetics, V2, P213, DOI DOI 10.4155/IPK-2017-0011
  • [5] Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics
    Daryaee, Fereidoon
    Tonge, Peter J.
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2019, 50 : 120 - 127
  • [6] EMA, 2023, EMA's regulatory science strategy to 2025--Mid-point achievements to end 2022
  • [7] EMA, 2023, REFL PAP US ART INT
  • [8] FDA, 2023, DISCUSSION PAPER REQ
  • [9] FDA, 2024, MOD INF DRUG DEV PAI
  • [10] FDA draft guidance for industry, 2024, EARLY ALZHEIMERS DIS
123